Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Avapritinib versus Placebo in Indolent Systemic Mastocytosis
Jason Gotlib, Mariana Castells, Hanneke Oude Elberink, et al.
NEJM Evidence (2023) Vol. 2, Iss. 6
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Challenges in Drug and Hymenoptera Venom Hypersensitivity Diagnosis and Management in Mastocytosis
Matthew P. Giannetti, Jennifer Nicoloro‐SantaBarbara, Grace Godwin, et al.
Diagnostics (2024) Vol. 14, Iss. 2, pp. 123-123
Open Access | Times Cited: 5
Management of Bone Health in Adult Mastocytosis
Yannick Degboé, C. Nezzar, Pauline Alary, et al.
Current Osteoporosis Reports (2025) Vol. 23, Iss. 1
Open Access
Indolent Systemic Mastocytosis: An Incidental Diagnosis
Ayesha Khalid, Arfa Faiz, Alan Kaell
Annals of Internal Medicine Clinical Cases (2025) Vol. 4, Iss. 3
Open Access
How we treat mast cell activation syndrome
Theo Gülen, Cem Akin
Annals of Allergy Asthma & Immunology (2025)
Closed Access
Mastocytosis in the age of precision medicine
Frank Siebenhaar, Randolf Brehler, Deborah Christen, et al.
Allergo Journal International (2025)
Open Access
Mastocytosis
Cem Akin, Michel Arock, Melody C. Carter, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access
Standardized indolent systemic mastocytosis evaluations across a healthcare system: implications for screening accuracy
Jeremy C. McMurray, Curtis S Pacheco, Brandon J. Schornack, et al.
Blood (2024)
Closed Access | Times Cited: 3
Mast cell disorders and Hymenoptera venom-triggered anaphylaxis: evaluation and management
Nathan A. Boggs, Ilaria Tanasi, Karin Hartmann, et al.
The Journal of Allergy and Clinical Immunology In Practice (2024)
Closed Access | Times Cited: 3
Increased TIM-3 and galectin-9 serum levels in patients with advanced systemic mastocytosis
Martina Konantz, Margaret S. Williams, Tamara Merkel, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 152, Iss. 4, pp. 1019-1024
Open Access | Times Cited: 6
Tyrosine Kinase Inhibitors in Non-advanced Systemic Mastocytosis
Cem Akin
Immunology and Allergy Clinics of North America (2023) Vol. 43, Iss. 4, pp. 743-750
Closed Access | Times Cited: 4
Efficacy and safety of mammalian target of rapamycin inhibitors in systemic mastocytosis: A nationwide French pilot study
Josquin Moraly, Julien Rossignol, Claire Rouzaud, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 6, pp. 1095-1102
Closed Access | Times Cited: 1
The Mastocytosis Control Test: A Patient-Reported Outcome Measure Assessing Disease Control
Frank Siebenhaar, Shazia Sofi, Sophia Neisinger, et al.
The Journal of Allergy and Clinical Immunology In Practice (2024) Vol. 13, Iss. 3, pp. 647-657.e3
Closed Access | Times Cited: 1
Anaphylaxis and systemic mastocytosis controlled with KIT inhibitors in a patient with metastatic lung adenocarcinoma
Camellia L. Hernandez, Donna‐Marie Lynch, Abby Jane Golash, et al.
Annals of Allergy Asthma & Immunology (2023) Vol. 131, Iss. 5, pp. 668-670
Closed Access | Times Cited: 3
The diagnostic workup for systemic mastocytosis differs from consensus recommendations: Results of a worldwide survey
Polina Pyatilova, Jonathan A. Bernstein, Felix Aulenbacher, et al.
World Allergy Organization Journal (2023) Vol. 16, Iss. 11, pp. 100838-100838
Open Access | Times Cited: 3
Evaluation of Bioequivalence for Avapritinib Tablets in Chinese Participants Under Fasting Conditions Using a Reference‐Scaled Average Bioequivalence Method
Zenglian Yue, Yin Wang, Li Zeng, et al.
Clinical Pharmacology in Drug Development (2024) Vol. 13, Iss. 6, pp. 672-676
Closed Access
Differentialdiagnose der Eosinophilie aus hämatologischer Sicht
Katja Sockel, Andreas Reiter, Martin Bornhäuser, et al.
Aktuelle Rheumatologie (2024) Vol. 49, Iss. 04, pp. 240-246
Closed Access
SOHO State of the Art Update and Next Questions: Current and Emerging Therapies for Systemic Mastocytosis
Helen T. Chifotides, Prithviraj Bose
Clinical Lymphoma Myeloma & Leukemia (2024)
Closed Access
Utility of KIT Mutations in Myeloid Neoplasms Without Documented Systemic Mastocytosis to Detect Hidden Mast Cells in Bone Marrow
Do H. Kim, Fuli Jia, Keyur P. Patel, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 11, pp. e878-e882
Open Access
Managing Systemic Mastocytosis
Jason Gotlib
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, pp. S19-S21
Closed Access
Systemic Mastocytosis: State of the Art
Isabel Farmer, Deepti Radia
Current Hematologic Malignancy Reports (2024) Vol. 19, Iss. 5, pp. 197-207
Closed Access
Case Report: Multidisciplinary management of a patient with indolent systemic mastocytosis and refractory symptoms
Matthew J. Hamilton, Greene Lw, Lauren M. Madigan, et al.
Frontiers in Allergy (2024) Vol. 5
Open Access
Mastocytosis demystified
Scott Veitch, Deepti Radia
Hematology (2023) Vol. 2023, Iss. 1, pp. 396-406
Closed Access | Times Cited: 1
Targeted Therapy for the Predominant Form of Mastocytosis
Dean D. Metcalfe
NEJM Evidence (2023) Vol. 2, Iss. 6
Closed Access
EXABS-115-MPN Current and Emerging Therapies for Systemic Mastocytosis
Prithviraj Bose
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, pp. S14-S17
Closed Access
Dermatologische Klinik des Universitätsspitals Basel
Karin Hartmann, Maja Brenner, Oliver Brandt, et al.
Aktuelle Dermatologie (2023) Vol. 49, Iss. 10, pp. 422-434
Closed Access
Page 1 - Next Page

Scroll to top